Business
Exercise of warrants
Aptamer Group plc (AIM: APTA) announced the exercise of warrants for 36,000,000 new ordinary shares at £0.002 per share, raising £72,000. These shares are expected to be admitted to trading on AIM around August 22, 2025. Following admission, the company will have 2,696,978,377 ordinary shares in issue, all with equal voting rights. Disclaimer*
About this update from Aptamer Group Plc
19 August 2025 Aptamer Group plc ("Aptamer", the "Company" or the "Group") Exercise of warrants Aptamer Group plc (AIM: APTA), the leading developer of next-generation synthetic binders delivering innovation to the life science industry, is pleased to announce that it has received notice to exercise warrants over a total of 36,000,000 new ordinary shares of £0.001 each in the Company ("Warrant Shares") at an exercise price of £0.002 per Warrant Share, raising £72,000 for the Company. Total voting rights An application will be made for the admission of these shares to trading on AIM, which is expected to become effective on or around 22 August 2025. Immediately following Admission, the Company will have 2,696,978,377 ordinary shares of £0.001 each in issue. The Company does not hold any shares in treasury, and all of the Ordinary Shares have equal voting rights. Therefore, the figures above represent the total voting rights in the Company and may be used by shareholders as the denominator for the calculations by which they can determine if they are required to notify their interest in, or a change to their interest in the Company under the Rules. - Ends - For further information, please contact: Aptamer Group plc Dr Arron Tolley, Chief Executive Officer +44 (0) 1904 217 404 SPARK Advisory Partners Limited - Nominated Adviser Andrew Emmott / Jade Bayat +44 (0) 20 3368 3550 Turner Pope Investments (TPI) Limited - Broker James Pope / Andrew Thacker +44 (0) 20 3657 0050 Northstar Communications Limited - Investor Relations Sarah Hollins +44 (0) 113 730 3896 About Aptamer Group Aptamer Group is a leading developer of next-generation synthetic binders delivering innovation to the life sciences industry. The Group develops Optimer® binders, advanced molecules that work like antibodies by attaching to specific targets in the body. These binders are used in medicine, diagnostic tests, and research tools, offering benefits like high stability, reliable performance, and lower costs compared to traditional antibodies. Aptamer operates a fee-for-service business in the US$210 billion market for antibody alternatives, working with all top 10 global pharmaceutical companies. It is also building valuable Optimer® assets with partners, aiming for future licensing revenue. Founded in 2008, the Group listed on the London Stock Exchange AIM market in December 2021 and is headquartered in York, UK. To register for news alerts by email go to https://aptamergroup.com/investors/investor-news-email-alerts/